[Successful surfactant therapy of ARDS in an immunodepressed child]

Area of Science:

• Pediatric critical care medicine
• Hematology-oncology
• Pulmonology

Background:

• Acute respiratory distress syndrome (ARDS) in children, often resulting from severe infections or immunosuppression, carries a high mortality rate.
• Current therapeutic guidelines for pediatric ARDS are lacking, leading to varied treatment approaches.
• Children with acute lymphatic leukemia undergoing immunosuppressive therapy are at increased risk for severe pulmonary complications.

Observation:

• A pediatric patient with acute lymphatic leukemia developed severe bronchopneumonia secondary to immunosuppressive therapy.
• During mechanical ventilation, the patient progressed to acute respiratory distress syndrome.
• The patient received surfactant therapy at a dose of 360 mg/kg body weight for 7 days.

Findings:

• Surfactant therapy was effective in managing the acute respiratory distress syndrome in this pediatric patient.
• Mechanical ventilation was required for 17 days.
• Lung function normalized within 3 weeks post-extubation, permitting the resumption of chemotherapy.

Implications:

• Surfactant administration may be a viable therapeutic option for pediatric ARDS, particularly in immunocompromised patients.
• This case highlights the importance of aggressive respiratory support in critically ill children with hematologic malignancies.
• Further controlled studies are warranted to establish definitive treatment protocols for pediatric ARDS.